{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:50:12Z","timestamp":1747173012845,"version":"3.40.5"},"reference-count":27,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S092427082100034X_as1\"><jats:title>Background:<\/jats:title><jats:p>The treatment of mania in bipolar disorders needs to be more efficient, as the manic condition creates severe problems for the patient when it comes to work, finances, relationships and health. This proof-of-concept study examines to what extent casein glycomacropeptide (CGMP) may reduce the precursors of dopamine, phenylalanine and tyrosine, in plasma, and therefore be a potential new intervention to treat acute manic episodes.<\/jats:p><\/jats:sec><jats:sec id=\"S092427082100034X_as2\"><jats:title>Method:<\/jats:title><jats:p>The study was designed as a double-blind randomised dose\u2013response study of CGMP (with added leucine and tryptophan) in 15 healthy men, receiving 3 different doses of CGMP with an interval of at least 14 days.<\/jats:p><\/jats:sec><jats:sec id=\"S092427082100034X_as3\"><jats:title>Results:<\/jats:title><jats:p>Administration of CGMP produced a dose-dependent depletion of plasma aromatic amino acids. The total area under the curve of plasma ratios of phenylalanine\u2013tyrosine compared to the level of leucine\u2013isoleucine\u2013valine\u2013-tryptophan was CGMP (20 g): 3.648 [SE:0.3281]; CGMP (40 g): 2.368 [SE:0.1858]; and CGMP (60 g)1.887 [SE:0.2591]. A comparison of the groups showed a dose-dependent statistical difference, with a one-way ANOVA summary (Dunnett) <jats:italic>F<\/jats:italic> = 11.87, <jats:italic>p<\/jats:italic> = 0.0003, CGMP 20 g versus CGMP 40 g, <jats:italic>p<\/jats:italic> = 0.0042, CGMP 20 g versus CGMP 60 g, <jats:italic>p<\/jats:italic> = 0.0002. No significant side effects were observed.<\/jats:p><\/jats:sec><jats:sec id=\"S092427082100034X_as4\"><jats:title>Conclusions:<\/jats:title><jats:p>This study demonstrate CGMP is a well-tolerated and effective mixture, and that 60 g of CGMP produced the highest depletion of plasma aromatic amino acids (phenylalanine and tyrosine). The effect seems to be highest after 3\u20134 h. We therefore conclude that this dose should be the one considered for future studies involving CGMP in humans.<\/jats:p><\/jats:sec>","DOI":"10.1017\/neu.2021.34","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T02:30:12Z","timestamp":1634697012000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":2,"title":["Dietary supplementation with casein glycomacropeptide, leucine and tryptophan reduces plasma amino acid levels in men"],"prefix":"10.1017","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-6410","authenticated-orcid":false,"given":"Erik Roj","family":"Larsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Juel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan R.","family":"Hollyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0081-0068","authenticated-orcid":false,"given":"Gregers","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"S092427082100034X_ref17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300665"},{"key":"S092427082100034X_ref2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.16"},{"key":"S092427082100034X_ref19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003396"},{"key":"S092427082100034X_ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.463003.x"},{"key":"S092427082100034X_ref26","first-page":"315","article-title":"Assessment of mood states in neurodegenerative disease: methodological issues and diagnostic recommendations","volume":"1","author":"Stern","year":"1996","journal-title":"Seminars in Clinical Neuropsychiatry"},{"volume-title":"Automated In-Needle Derivatization Applying a User-Defined Program for the Thermo Scientific Dionex WPS-3000 Split-Loop Autosampler","year":"2015","key":"S092427082100034X_ref12"},{"key":"S092427082100034X_ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s007260170063"},{"key":"S092427082100034X_ref1","first-page":"207","article-title":"Assessment of mood state in patients undergoing electroconvulsive therapy: the utility of visual analog mood scales developed for cognitively impaired patients","volume":"12","author":"Arruda","year":"1996","journal-title":"Convulsive Therapy"},{"key":"S092427082100034X_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(00)00309-8"},{"key":"S092427082100034X_ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-016-2057-z"},{"key":"S092427082100034X_ref23","doi-asserted-by":"publisher","DOI":"10.1177\/026988119601000309"},{"key":"S092427082100034X_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy012"},{"key":"S092427082100034X_ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.4.356"},{"key":"S092427082100034X_ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2018.00243"},{"key":"S092427082100034X_ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1975.tb01572.x"},{"key":"S092427082100034X_ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.21.12079"},{"key":"S092427082100034X_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07044-4"},{"key":"S092427082100034X_ref24","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"The Journal of Clinical Psychiatry"},{"key":"S092427082100034X_ref11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001423"},{"key":"S092427082100034X_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-013-3191-9"},{"key":"S092427082100034X_ref22","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.3.210"},{"key":"S092427082100034X_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.07.059"},{"key":"S092427082100034X_ref5","doi-asserted-by":"publisher","DOI":"10.1002\/9781118511800"},{"key":"S092427082100034X_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"S092427082100034X_ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0269215512442670"},{"key":"S092427082100034X_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2826.2011.02266.x"},{"key":"S092427082100034X_ref7","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.6.893"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S092427082100034X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T11:24:03Z","timestamp":1647257043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S092427082100034X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S092427082100034X"],"URL":"https:\/\/doi.org\/10.1017\/neu.2021.34","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"type":"print","value":"0924-2708"},{"type":"electronic","value":"1601-5215"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"\u00a9 The Author(s), 2021. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}